|
Prof. Reisner, a renowned expert in transplantation technology, holds the Henry Drake chair of Immunology at the Weizmann Institute of Science. He earned his M.Sc. at the University of California, Berkely and his Ph.D. at the Weizmann Institute of Science, Rehovot, Israel. Prof. Reisner has pioneered and popularized techniques for bone marrow transplantation with partially matched donor tissue. He is a member of the Advisory Committee of the American Society of Hematology Scientific committee on transplantation Biology and has been a visiting professor at the Memorial Sloane Kettering Cancer Center, Harvard University and Columbia University.
Prof. Reisner has published widely in leading scientific journals and serves as an Associate Editor for the Journal for Experimental Hematology, as a co-editor of an electronic quarterly on haploidentical bone marrow transplantation (www.haplo.org) and on the editorial board of a number of publications. Since 1993 Prof. Reisner, who was a founder of XTL Biopharmaceuticals Ltd., has served as a member of the Scientific Advisory Board of that company. XTL has developed fully human monoclonal antibodies for the treatment of hepatitis B and C. | 